Contract analysis

I. Executive Summary The purpose of this memorandum is to provide a comprehensive legal framework for evaluating the transfer pricing positions of Penterra Pharmaceuticals Corp. ("PPC" or the "Company") in connection with the examination initiated by the Internal Revenue Service Large Business & International Division ("LB&I"). On May 16, 2022, the IRS issued Letter 2205-A to PPC, formally opening an examination of t

II. Scope and Background A. Engagement Context Calderwood & Harkness LLP was engaged by Penterra Pharmaceuticals Corp. on June 2, 2022, as outside tax counsel to represent and defend PPC in connection with the IRS examination of its federal income tax returns for tax years 2017, 2018, 2019, and 2020. The engagement letter, executed by PPC's Senior Vice President and General Tax Counsel, Rebecca Thornton, provides for

1. Cost-Sharing Arrangement (CSA) The CSA was executed effective July 1, 2012, between PPC and PBI (through PHL, disregarded). Under the CSA, PBI acquired the right to develop and exploit PPC's pharmaceutical IP portfolio outside the Americas—defined to encompass all territories other than North America, Central America, South America, and the Caribbean—in exchange for: (a) a lump-sum PCT payment of $312 million, rep

2. Legacy IP Royalty Arrangement Separate from the CSA, PBI licensed certain pre-2012 vintage legacy compounds from PPC pursuant to a formal license agreement executed contemporaneously with the CSA. The legacy IP royalty arrangement covers pharmaceutical compounds that were fully developed and commercialized prior to the effective date of the CSA and that were not contributed to the CSA's intangible development prog

3. Key Products PPC's product portfolio includes several significant pharmaceutical products that generate substantial global revenues. The three most commercially significant products are: Veritaxol — PPC's oncology blockbuster. Veritaxol is a monoclonal antibody indicated for the treatment of advanced non-small cell lung cancer and metastatic colorectal cancer. For fiscal year 2020, Veritaxol generated global net s

4. Contemporaneous Transfer Pricing Documentation PPC's contemporaneous transfer pricing documentation for all four tax years at issue (2017, 2018, 2019, and 2020) was prepared by Crestfield & Associates LLP, under the supervision of Susan Lam, Transfer Pricing Partner. The documentation was prepared to meet the standards set forth in IRC § 6662(e) and the associated regulations for penalty protection purposes. The d

III. Statutory Framework: IRC § 482 A. Text and Purpose of IRC § 482

Section 482 of the Internal Revenue Code provides the statutory authority for the Secretary of the Treasury, acting through the Internal Revenue Service, to allocate gross income, deductions, credits, or allowances among two or more organizations, trades, or businesses that are owned or controlled, directly or indirectly, by the same interests. The statute provides, in relevant part: "In any case of two or more organ

1. Functions Performed The functional analysis is the starting point of any transfer pricing comparability assessment. Treas. Reg. § 1.482-1(d)(3)(i) requires consideration of the functions performed by each party to the controlled transaction, the assets employed, and the risks assumed. The functional analysis establishes the economic profile of each party and determines the appropriate characterization of the trans

2. Contractual Terms Treas. Reg. § 1.482-1(d)(3)(ii) provides that arm's-length parties typically formalize their dealings in contracts that reflect the economic substance of their arrangement. The regulations recognize that contract terms—including provisions regarding payment, duration, termination, volume, and scope of rights—can materially affect the pricing of a transaction and must be considered in the comparab

3. Risks Assumed Treas. Reg. § 1.482-1(d)(3)(iii) requires consideration of the risks assumed by each party to the controlled transaction. Risk allocation is a critical factor in the comparability analysis because the assumption of economically significant risks is a key driver of profit potential. A party that bears greater risk is generally entitled to greater compensation. In PPC's case, PBI bears significant risk

4. Economic Conditions Treas. Reg. § 1.482-1(d)(3)(iv) requires consideration of the economic conditions prevailing in the markets in which the controlled and uncontrolled transactions take place. Relevant economic conditions include market size, level of competition, availability of substitute goods or services, purchasing power, regulatory environment, and geographic location. The pharmaceutical industry presents u

5. Property or Services Transferred Treas. Reg. § 1.482-1(d)(3)(v) requires consideration of the nature of the property or services transferred in the controlled transaction. In PPC's case, the property at issue consists of pharmaceutical intangible property—specifically, patents, trade secrets, know-how, clinical data, regulatory filings and approvals, and associated rights relating to PPC's oncology, immunology, an

6. Actual Conduct Principle The regulations emphasize that the economic substance of a transaction, not merely its legal form, controls the transfer pricing analysis. Treas. Reg. § 1.482-1(d)(3)(ii)(B) provides that where the actual conduct of the parties is inconsistent with the written terms of their agreement, the IRS may disregard the contractual provisions and determine the true terms of the transaction based on

IV. The Best Method Rule — Treas. Reg. § 1.482-1(c) A. Overview The best method rule is the cornerstone of method selection under IRC § 482 and its implementing regulations. Treasury Regulation § 1.482-1(c) provides: "The arm's length result of a controlled transaction must be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's length result." This decep

1. Degree of Comparability The first and most important factor is the degree of comparability between the controlled transaction and the uncontrolled transactions, comparables, or other data used in applying the method. The method that relies on the closest factual comparables—considering all of the comparability factors described in Treas. Reg. § 1.482-1(d) and discussed in Section III.C above—is generally the most

2. Quality of Data and Assumptions The second factor is the quality of the data and assumptions used in applying the method. See Treas. Reg. § 1.482-1(c)(2)(ii). Methods that require fewer and more reliable assumptions produce more reliable results. For example, the CUT method, when highly comparable uncontrolled transactions are available, requires relatively few assumptions beyond the comparability adjustments them

3. Sensitivity of Results to Deficiencies in Data and Assumptions The third factor is the sensitivity of the method's results to deficiencies in the data or assumptions used. See Treas. Reg. § 1.482-1(c)(2)(iii). Some methods are inherently more sensitive than others to data imperfections. For example, the income method for PCT valuation is highly sensitive to the discount rate and revenue projection assumptions: sma

1. Comparable Uncontrolled Transaction (CUT) Method The CUT method evaluates whether the amount charged in a controlled transfer of intangible property is arm's-length by reference to the amount charged in comparable uncontrolled transactions involving the transfer of the same or comparable intangible property under comparable circumstances. See Treas. Reg. § 1.482-4(c). The CUT method is the most direct method for d

2. Comparable Profits Method (CPM) The comparable profits method evaluates whether the amount charged in a controlled transaction is arm's-length based on objective measures of profitability (profit level indicators or "PLIs") derived from uncontrolled taxpayers that engage in comparable activities under comparable circumstances. See Treas. Reg. § 1.482-5. The CPM corresponds to the Transactional Net Margin Method ("

3. Profit Split Method The profit split method divides the combined operating profit (or loss) from controlled transactions according to the relative value of each party's contributions to the combined profit. See Treas. Reg. § 1.482-6. This method is most appropriate where both parties to the controlled transaction make unique and valuable contributions that cannot readily be benchmarked against uncontrolled compara

4. Income Method (for PCT Valuation) The income method is specifically authorized under Treas. Reg. § 1.482-7(g)(4) for valuing platform contribution transactions in the context of qualified cost-sharing arrangements. The income method determines the arm's-length value of the pre-existing intangible property contributed to the CSA by discounting the anticipated future income attributable to that property at an approp

5. Unspecified Methods Finally, the regulations permit the use of methods not specifically described in the regulations if such methods produce the most reliable arm's-length result. See Treas. Reg. § 1.482-4(d). The use of unspecified methods is relatively uncommon and is most likely to arise where the specified methods are inadequate to capture the unique economic characteristics of a particular transaction. D. App

1. Legacy IP Royalty — CUT Method PPC's contemporaneous documentation applies the CUT method to the 4.5% legacy IP royalty rate, identifying comparable third-party pharmaceutical license agreements as the basis for determining the arm's-length royalty rate. The CUT method is the best method for this transaction for several reasons. First, comparable pharmaceutical license agreements are identifiable. The pharmaceutic

2. CSA Cost-Sharing — Reasonably Anticipated Benefits Method Under Treas. Reg. § 1.482-7(e), the share of intangible development activity costs borne by each participant in a qualified cost-sharing arrangement must be proportional to that participant's share of the reasonably anticipated benefits from the IDA. The RAB method is the prescribed regulatory method for determining cost-sharing ratios under a QCSA, and it

3. PCT Valuation — Income Method/DCF Under Treas. Reg. § 1.482-7(g), the PCT payment must reflect the arm's-length charge for the pre-existing intangible property contributed by a participant to the CSA. PPC used the income method, as described in Treas. Reg. § 1.482-7(g)(4), to value the pre-existing IP contributed to the CSA as of July 1, 2012. The income method is the most commonly used and most reliable method fo